MA46661B1 - Formulations de vaccin glycoconjugué dirigé contre expec - Google Patents
Formulations de vaccin glycoconjugué dirigé contre expecInfo
- Publication number
- MA46661B1 MA46661B1 MA46661A MA46661A MA46661B1 MA 46661 B1 MA46661 B1 MA 46661B1 MA 46661 A MA46661 A MA 46661A MA 46661 A MA46661 A MA 46661A MA 46661 B1 MA46661 B1 MA 46661B1
- Authority
- MA
- Morocco
- Prior art keywords
- directed against
- vaccine formulations
- expec
- glycoconjugate vaccine
- against expec
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000006353 environmental stress Effects 0.000 abstract 1
- 239000002095 exotoxin Substances 0.000 abstract 1
- 231100000776 exotoxin Toxicity 0.000 abstract 1
- 150000004676 glycans Chemical group 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229940031348 multivalent vaccine Drugs 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
L'invention concerne des compositions et des méthodes pour induire une réponse immunitaire contre escherichia coli pathogène extra-intestinal (expec). En particulier, l'invention concerne des vaccins multivalents contenant un polysaccharide d'antigène e coli lié de manière covalente à une exotoxine a de protéine porteuse pseudomonas aeruginosa (epa) pouvant résister à de multiples contraintes environnementales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16195256 | 2016-10-24 | ||
PCT/EP2017/077123 WO2018077853A1 (fr) | 2016-10-24 | 2017-10-24 | Formulations de vaccin glycoconjugué dirigé contre expec |
Publications (2)
Publication Number | Publication Date |
---|---|
MA46661A MA46661A (fr) | 2019-08-28 |
MA46661B1 true MA46661B1 (fr) | 2024-02-29 |
Family
ID=57206056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA46661A MA46661B1 (fr) | 2016-10-24 | 2017-10-24 | Formulations de vaccin glycoconjugué dirigé contre expec |
Country Status (24)
Country | Link |
---|---|
US (5) | US10159751B2 (fr) |
EP (1) | EP3528839B1 (fr) |
JP (1) | JP6698220B2 (fr) |
KR (1) | KR102576346B1 (fr) |
CN (1) | CN109996559A (fr) |
AR (1) | AR109621A1 (fr) |
AU (1) | AU2017349163B2 (fr) |
BR (1) | BR112019007803A2 (fr) |
CA (1) | CA3038705A1 (fr) |
CL (1) | CL2019001104A1 (fr) |
CO (1) | CO2019003949A2 (fr) |
EA (1) | EA201991033A1 (fr) |
ES (1) | ES2966895T3 (fr) |
HR (1) | HRP20240171T1 (fr) |
IL (1) | IL266080B (fr) |
MA (1) | MA46661B1 (fr) |
MX (2) | MX2019004689A (fr) |
MY (1) | MY191842A (fr) |
PH (1) | PH12019500561A1 (fr) |
PL (1) | PL3528839T3 (fr) |
RS (1) | RS65125B1 (fr) |
SG (1) | SG11201902567WA (fr) |
TW (1) | TWI734853B (fr) |
WO (1) | WO2018077853A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2718051T3 (es) | 2013-01-17 | 2019-06-27 | Arsanis Biosciences Gmbh | Antígeno específico de E. coli MDR |
CA2940547C (fr) | 2014-02-24 | 2021-01-05 | Glycovaxyn Ag | Nouveau polysaccharide et utilisations associees |
TWI715617B (zh) * | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
CA3134216A1 (fr) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugues d'antigenes polysaccharidiques o d'e. coli, procedes de production de ces derniers, et methodes d'utilisation de ces derniers |
CA3134045A1 (fr) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Procedes de production de bioconjugues de polysaccharides o-antigenes d' e. coli, compositions de ceux-ci et leurs procedes d'utilisation |
AU2021342797B2 (en) | 2020-09-17 | 2024-02-08 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
WO2022214620A1 (fr) | 2021-04-08 | 2022-10-13 | Janssen Pharmaceuticals, Inc. | Procédé de production de bioconjugués |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422653D0 (en) | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
AUPM399594A0 (en) | 1994-02-21 | 1994-03-17 | Csl Limited | Antigenic preparation for treatment or prevention of helicobacter infection |
FI102976B (fi) | 1994-02-28 | 1999-03-31 | Valtion Teknillinen | Menetelmä lisäkeittokemikaalien tuottamiseksi sekä käyttämiseksi sulfa attiselluloosaprosessissa |
US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
JP2004515450A (ja) | 2000-04-18 | 2004-05-27 | エンドバイオロジックス, インコーポレイテッド | 敗血症処置のためのリポ多糖結合体ワクチン |
RU2189253C1 (ru) | 2001-04-09 | 2002-09-20 | Государственный научный центр прикладной микробиологии | Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения |
WO2003074679A2 (fr) | 2002-03-01 | 2003-09-12 | Xencor | Optimisation d'anticorps |
ES2258214T3 (es) | 2002-03-07 | 2006-08-16 | Eidgenossische Technische Hochschule Zurich | Sistema y procedimiento para la produccion de proteinas glucosiladas recombinantes en un huesped procariotico. |
ES2523655T5 (es) * | 2002-06-21 | 2018-04-23 | Novo Nordisk Health Care Ag | Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa |
AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
CA2530531A1 (fr) * | 2003-06-30 | 2005-01-20 | Alza Corporation | Formulations pour microprojections revetues contenant des contre-ions non volatils |
EP2289911A3 (fr) | 2004-03-30 | 2011-03-30 | NsGene A/S | Utilisation thérapeutique du facteur de croissance nsg33 |
WO2005117948A1 (fr) * | 2004-06-01 | 2005-12-15 | Ares Trading S.A. | Procede de stabilisation de proteines |
US20060134141A1 (en) * | 2004-12-14 | 2006-06-22 | Nabi Biopharmaceuticals | Glycoconjugate vaccines containing peptidoglycan |
KR101524636B1 (ko) | 2005-05-11 | 2015-06-03 | 에테하 취리히 | 원핵 세포로부터의 재조합 n-글리코실화 단백질 |
CA2646891A1 (fr) | 2006-03-23 | 2007-09-27 | Novartis Ag | Composes de potentialisation immunitaire |
CA2646539A1 (fr) | 2006-03-23 | 2007-09-27 | Novartis Ag | Composes d'imidazoquinoxaline utilises en tant qu'immunomodulateurs |
JP4791866B2 (ja) | 2006-03-24 | 2011-10-12 | 国立大学法人秋田大学 | 下痢原性大腸菌感染症の判別に用いられる固相等 |
EP2193146B1 (fr) | 2007-09-14 | 2016-05-25 | Adimab, LLC | Bibliothèques d'anticorps synthétiques rationnelles et leurs utilisations |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
JP5647899B2 (ja) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
SI2257307T1 (sl) | 2008-02-20 | 2018-09-28 | Glaxosmithkline Biologicals S.A. | Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic |
SG175142A1 (en) | 2009-04-27 | 2011-12-29 | Immuron Ltd | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
EP2475393A4 (fr) * | 2009-09-14 | 2013-08-21 | Vu Truong-Le | Formulation pour la stabilisation à température ambiante d'un vaccin bactérien atténué vivant |
PT2501406T (pt) | 2009-11-19 | 2018-02-21 | Glaxosmithkline Biologicals Sa | Sistema de biossíntese que produz polissacáridos imunogénicos em células procariotas |
EP4219805A1 (fr) | 2010-07-16 | 2023-08-02 | Adimab, LLC | Banques d'anticorps |
BR112013005049A2 (pt) * | 2010-09-02 | 2016-05-31 | Sanofi Pasteur | estabilizador para a preparação de uma composição vacina da pólio seca injetável |
WO2012078482A1 (fr) * | 2010-12-10 | 2012-06-14 | Merck Sharp & Dohme Corp. | Nouvelles formulations réduisant l'aggrégation induite par l'agitation de compositions immunogènes |
ES2639122T3 (es) * | 2011-05-13 | 2017-10-25 | Zoetis Services Llc | Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah |
JP2014526449A (ja) | 2011-09-06 | 2014-10-06 | グリコヴァキシン アーゲー | 原核細胞において製造されるバイオコンジュゲートワクチン |
WO2013038385A2 (fr) * | 2011-09-14 | 2013-03-21 | Novartis Ag | Combinaison de vaccin contre escherichia coli |
US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
BR112015004817A2 (pt) | 2012-09-10 | 2017-07-04 | Glycovaxyn Ag | bioconjugados compreendendo antígenos modificados e seus usos |
EP3527663B1 (fr) | 2012-10-12 | 2021-12-01 | GlaxoSmithKline Biologicals SA | Methode pour modifier des cellules |
US10287330B2 (en) | 2012-12-27 | 2019-05-14 | Glaxosmithkline Biologicals S.A. | Methods and compositions relating to CRM197 |
ES2718051T3 (es) | 2013-01-17 | 2019-06-27 | Arsanis Biosciences Gmbh | Antígeno específico de E. coli MDR |
GB201301085D0 (en) * | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
SG11201506499YA (en) * | 2013-03-15 | 2015-09-29 | Glaxosmithkline Ip No 2 Ltd | Low concentration antibody formulations |
EA201690529A1 (ru) | 2013-10-11 | 2016-11-30 | Гликоваксин Аг | Способы модификации клетки-хозяина |
PE20212335A1 (es) * | 2014-01-21 | 2021-12-16 | Pfizer | Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos |
CN106536551B (zh) | 2014-02-06 | 2021-04-16 | X4制药(奥地利)有限责任公司 | 大肠杆菌特异性抗体序列 |
CA2940547C (fr) * | 2014-02-24 | 2021-01-05 | Glycovaxyn Ag | Nouveau polysaccharide et utilisations associees |
BE1022998B1 (fr) | 2014-12-30 | 2016-10-28 | Glycovaxyn Ag | Compositions et procédés de glycosylation de protéines |
TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
CA3134216A1 (fr) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugues d'antigenes polysaccharidiques o d'e. coli, procedes de production de ces derniers, et methodes d'utilisation de ces derniers |
CA3134045A1 (fr) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Procedes de production de bioconjugues de polysaccharides o-antigenes d' e. coli, compositions de ceux-ci et leurs procedes d'utilisation |
-
2017
- 2017-10-23 AR ARP170102949A patent/AR109621A1/es unknown
- 2017-10-24 CA CA3038705A patent/CA3038705A1/fr active Pending
- 2017-10-24 MA MA46661A patent/MA46661B1/fr unknown
- 2017-10-24 US US15/792,242 patent/US10159751B2/en active Active
- 2017-10-24 EP EP17794931.0A patent/EP3528839B1/fr active Active
- 2017-10-24 JP JP2019521766A patent/JP6698220B2/ja active Active
- 2017-10-24 ES ES17794931T patent/ES2966895T3/es active Active
- 2017-10-24 MY MYPI2019002160A patent/MY191842A/en unknown
- 2017-10-24 MX MX2019004689A patent/MX2019004689A/es unknown
- 2017-10-24 PL PL17794931.0T patent/PL3528839T3/pl unknown
- 2017-10-24 EA EA201991033A patent/EA201991033A1/ru unknown
- 2017-10-24 CN CN201780065201.1A patent/CN109996559A/zh active Pending
- 2017-10-24 SG SG11201902567WA patent/SG11201902567WA/en unknown
- 2017-10-24 RS RS20240125A patent/RS65125B1/sr unknown
- 2017-10-24 AU AU2017349163A patent/AU2017349163B2/en active Active
- 2017-10-24 TW TW106136594A patent/TWI734853B/zh active
- 2017-10-24 WO PCT/EP2017/077123 patent/WO2018077853A1/fr active Application Filing
- 2017-10-24 BR BR112019007803A patent/BR112019007803A2/pt unknown
- 2017-10-24 HR HRP20240171TT patent/HRP20240171T1/hr unknown
- 2017-10-24 KR KR1020197011812A patent/KR102576346B1/ko active IP Right Grant
-
2018
- 2018-11-15 US US16/191,659 patent/US10525145B2/en active Active
-
2019
- 2019-03-15 PH PH12019500561A patent/PH12019500561A1/en unknown
- 2019-04-16 IL IL266080A patent/IL266080B/en unknown
- 2019-04-18 CO CONC2019/0003949A patent/CO2019003949A2/es unknown
- 2019-04-22 MX MX2023004834A patent/MX2023004834A/es unknown
- 2019-04-23 CL CL2019001104A patent/CL2019001104A1/es unknown
- 2019-12-10 US US16/709,223 patent/US11033633B2/en active Active
-
2021
- 2021-05-12 US US17/318,616 patent/US11844766B2/en active Active
-
2023
- 2023-11-07 US US18/503,294 patent/US20240082412A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46661B1 (fr) | Formulations de vaccin glycoconjugué dirigé contre expec | |
EP4245320A3 (fr) | Méthodes et compositions pour une protection immunitaire contre e. coli pathogène extra-intestinale | |
EA201691478A1 (ru) | Новый полисахарид и его применения | |
EP3556353A3 (fr) | Adjuvants de vaccins à nanoparticules lipidiques et systèmes d'administration d'antigènes | |
MA41265B1 (fr) | Compositions pour administration de médicaments iléo-jéjunal. | |
MX2010005871A (es) | Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa. | |
NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
EA201890417A1 (ru) | Генетически кодируемые, внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения | |
MX351148B (es) | Formulacion de anticuerpo beta amiloide. | |
AR082952A1 (es) | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis | |
CO2021001926A2 (es) | Composiciones de escherichia coli y métodos de estas | |
WO2015175355A8 (fr) | Compositions et procédés d'augmentation de l'immunogénicité de conjugués polysaccharide-protéine | |
MX2017003121A (es) | Formulaciones de anticuerpos. | |
MA45283A1 (fr) | Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela | |
EA202091690A1 (ru) | Иммуногенная композиция, содержащая стафилококковые антигены | |
MX2022015734A (es) | Proteinas de exotoxina a modificadas. | |
MX2014009660A (es) | Formulacion de anticuerpo anti-selectina p. | |
MA39228A1 (fr) | Compositions à utiliser pour le traitement d'états allergiques | |
MX2015011692A (es) | Suspension de proteinas como un sistema opacificante de bebidas. | |
AR105793A1 (es) | Métodos y composiciones para protección inmunológica contra e. coli patogénica extraintestinal | |
AR116010A1 (es) | Composiciones de escherichia coli y métodos de estas | |
AR114693A1 (es) | Vacunas contra infecciones intraabdominales | |
MX2022001937A (es) | Composicion inmunogenica. | |
MA38131A3 (fr) | Thérapie adjuvante par inhibiteur de kinase de la famille tec | |
TH162727A (th) | สารเพิ่มความเสถียรต่อแสงชนิดใหม่ |